Dr. Myong-Jin (MJ) Kim serves as a director of Div of Therapeutic Performance II, Office of Research and Standards, Office of Generic Drugs, CDER, US FDA. Dr. Kim leads the group that leverages expertise in clinical pharmacology, formulation science and human subject protection to conduct research that ensures therapeutic equivalence of generic versions of oral drug products, and to develop product-specific guidances for generic drug developers. She recently served as the FDA Deputy Topic Lead for the ICH Expert Working Group on M13: Bioequivalence for Immediate Release Solid Oral Dosage Forms.

Dr. Kim currently serves as the Secretary of the American College of Clinical Pharmacology (ACCP), Member of the Board of Regents and the chair of the Inclusivity, Diversity and Equity Committee within the ACCP. Her other ACCP volunteer efforts include past pr present service as a member of the Strategic Planning Committee, Publication Committee, Annual Meeting Program Committee and Honors and Awards Committee. She is the recipient of the FDA Outstanding Inter-Center Scientific Collaboration Award, CDER Center Director’s Special Citation, CDER Special Recognition Award and FDA Outstanding Service Award. Dr. Kim is on the editorial boards of The Journal of Clinical Pharmacology and Clinical Pharmacology & Therapeutics. Lastly, she is the recipient of the American Society for Clinical Pharmacology and Therapeutics Mentor Award for serving in a mentoring role and making a significant impact in the career of her mentees.

Dr. Kim graduated from the Georgia Inst of Technology in Atlanta, GA, with a Bachelor of Science in chemistry. Subsequently, she received a Doctor of Pharmacy from the Temple Univ School of Pharmacy in Philadelphia, PA and completed her postdoctoral training in Clinical Pharmacology at Bassett Healthcare in Cooperstown, NY.